Literature DB >> 21743212

Dyslipidemia in dialysis patients.

Ahmed H Mitwalli1, Awatif A Alam, Jamal S Al Wakeel, Arthur C Isnani.   

Abstract

In order to evaluate the lipid profiles of dialysis patients, we retrospectively reviewed all the chronic kidney disease (CKD) patients on chronic hemodialysis (HD) or continuous ambulatory peritoneal dialysis (CAPD), followed up between June 2004 and May 2005, in two tertiary hospitals in Riyadh, Saudi Arabia. There were 380 patients including 206 (54.2%) females and the mean age of the patients was 45.9 ± 15.8 years. The mean dialysis duration was 65.0 ± 58.3 months. Diabetes was present in 97 (25.5%) of the patients and hypertension in 84 (22.1%). Younger patients had more disturbed lipid profile than elderly patients, and females had higher lipid values than males. The CAPD patients had worse lipid profile than those on HD, irrespective of age, sex and duration of dialysis. The presence of diabetes, hypertension, smoking and cardiovascular disease (CVD) all contributed to the worsening of lipid profiles of our patients. Dialysis patients showed improvement in lipid profile initially followed by gradual deterioration. We conclude that dyslipidemia, which increases the risk of CVD by increasing atherogenesis, progresses over time in dialysis patients and becomes worse in CAPD patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21743212

Source DB:  PubMed          Journal:  Saudi J Kidney Dis Transpl        ISSN: 1319-2442


  2 in total

1.  Risk factors for mortality in Chinese patients on continuous ambulatory peritoneal dialysis.

Authors:  Fan Zhang; Hong Liu; Xiaoli Gong; Fuyou Liu; Youming Peng; Meichu Cheng; Hongqing Zhang; Yang Liu; Yuyuan Liu; Chunyan Guo
Journal:  Perit Dial Int       Date:  2014-09-02       Impact factor: 1.756

2.  Calcium-sensing receptor gene (CASR) polymorphisms and CASR transcript level concerning dyslipidemia in hemodialysis patients: a cross-sectional study.

Authors:  Alicja E Grzegorzewska; Bartosz A Frycz; Monika Świderska; Leszek Niepolski; Adrianna Mostowska; Paweł P Jagodziński
Journal:  BMC Nephrol       Date:  2019-11-27       Impact factor: 2.388

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.